A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Virally-Suppressed Adult Subjects with Chronic Hepatitis B
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Selgantolimod (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 08 Nov 2019 Results presented at the Gilead Sciences Media Release.
- 30 Sep 2019 Planned End Date changed from 1 Feb 2020 to 1 Aug 2020.
- 05 Mar 2019 Planned End Date changed from 1 Sep 2019 to 1 Feb 2020.